|
1
|
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J,
Barlogie B and Shaughnessy J Jr: Cyclin D dysregulation: An early
and unifying pathogenic event in multiple myeloma. Blood.
106:296–303. 2005. View Article : Google Scholar
|
|
2
|
Herrinton LJ, Demers PA, Koepsell TD,
Weiss NS, Daling JR, Taylor JW, Lyon JL, Swanson GM and Greenberg
RS: Epidemiology of the M-component immunoglobulin types of
multiple myeloma. Cancer Causes Control. 4:83–92. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lyubimova NV, Timofeev YS, Abaev VM,
Votyakova OM and Kushlinskii NE: Immunochemical Diagnosis of
Multiple Myeloma. Bull Exp Biol Med. 165:84–87. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
No authors listed. Pharmacokinetics and
pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and
non-human primates. Mol Ther Nucleic Acids. 5:e3362016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo J, McKenna SL, O’Dwyer ME, Cahill MR
and O’Driscoll CM: RNA interference for multiple myeloma therapy:
Targeting signal transduction pathways. Expert Opin Ther Targets.
20:107–121. 2016. View Article : Google Scholar
|
|
6
|
Liang B, Yin JJ and Zhan XR: MiR-301a
promotes cell proliferation by directly targeting TIMP2 in multiple
myeloma. Int J Clin Exp Pathol. 8:9168–9174. 2015.PubMed/NCBI
|
|
7
|
Yang Y, Li F, Saha MN, Abdi J, Qiu L and
Chang H: miR-137 and miR-197 Induce Apoptosis and Suppress
Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. Clin Cancer
Res. 21:2399–2411. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calura E, Bisognin A, Manzoni M, Todoerti
K, Taiana E, Sales G, Morgan GJ, Tonon G, Amodio N, Tassone P, et
al: Disentangling the microRNA regulatory milieu in multiple
myeloma: Integrative genomics analysis outlines mixed miRNA-TF
circuits and pathway-derived networks modulated in t(4;14)
patients. Oncotarget. 7:2367–2378. 2016. View Article : Google Scholar :
|
|
9
|
Yang WC and Lin SF: Mechanisms of drug
resistance in relapse and refractory multiple myeloma. BioMed Res
Int. 2015:3414302015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Di Martino MT, Leone E, Amodio N, Foresta
U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli
E, et al: Synthetic miR-34a mimics as a novel therapeutic agent for
multiple myeloma: In vitro and in vivo evidence. Clin Cancer Res.
18:6260–6270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Du J, Liu S, He J, Liu X, Qu Y, Yan W, Fan
J, Li R, Xi H, Fu W, et al: MicroRNA-451 regulates stemness of side
population cells via PI3K/Akt/mTOR signaling pathway in multiple
myeloma. Oncotarget. 6:14993–15007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng P, Guo H, Li G, Han S, Luo F and Liu
Y: PSMB4 promotes multiple myeloma cell growth by activating
NF-κB-miR-21 signaling. Biochem Biophys Res Commun. 458:328–333.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grasedieck S, Sorrentino A, Langer C,
Buske C, Döhner H, Mertens D and Kuchenbauer F: Circulating
microRNAs in hematological diseases: Principles, challenges, and
perspectives. Blood. 121:4977–4984. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rocci A, Hofmeister CC, Geyer S, Stiff A,
Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T,
et al: Circulating miRNA markers show promise as new
prognosticators for multiple myeloma. Leukemia. 28:1922–1926. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li F, Xu Y, Deng S, Li Z, Zou D, Yi S, Sui
W, Hao M and Qiu L: MicroRNA-15a/16-1 cluster located at chromosome
13q14 is downregulated but displays different expression pattern
and prognostic significance in multiple myeloma. Oncotarget.
6:38270–38282. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang X, Zhong X, Tanyi JL, Shen J, Xu C,
Gao P, Zheng TM, DeMichele A and Zhang L: mir-30d Regulates
multiple genes in the autophagy pathway and impairs autophagy
process in human cancer cells. Biochem Biophys Res Commun.
431:617–622. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye Z, Zhao L, Li J, Chen W and Li X:
miR-30d blocked transforming growth factor β1-induced
epithelial-mesenchymal transition by targeting snail in ovarian
cancer cells. Int J Gynecol Cancer. 25:1574–1581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao JJ, Lin J, Zhu D, Wang X, Brooks D,
Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, et al: miR-30-5p
functions as a tumor suppressor and novel therapeutic tool by
targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res.
74:1801–1813. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu C, Jin B, Chen L, Zhuo D, Zhang Z, Gong
K and Mao Z: MiR-30d induces apoptosis and is regulated by the
Akt/FOXO pathway in renal cell carcinoma. Cell Signal.
25:1212–1221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wan L, Hu G, Wei Y, Yuan M, Bronson RT,
Yang Q, Siddiqui J, Pienta KJ and Kang Y: Genetic ablation of
metadherin inhibits autochthonous prostate cancer progression and
metastasis. Cancer Res. 74:5336–5347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu G, Chong RA, Yang Q, Wei Y, Blanco MA,
Li F, Reiss M, Au JL, Haffty BG and Kang Y: MTDH activation by 8q22
genomic gain promotes chemoresistance and metastasis of
poor-prognosis breast cancer. Cancer Cell. 15:9–20. 2009.
View Article : Google Scholar :
|
|
22
|
Yao Y, Gu X, Liu H, Wu G, Yuan D, Yang X
and Song Y: Metadherin regulates proliferation and metastasis via
actin cytoskeletal remodelling in non-small cell lung cancer. Br J
Cancer. 111:355–364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Wang D, Liu H, Feng Y, Zhu T, Zhang
L, Zhu B and Zhang Y: Knockdown of astrocyte elevated gene-1
(AEG-1) in cervical cancer cells decreases their invasiveness,
epithelial to mesenchymal transition, and chemoresistance. Cell
Cycle. 13:1702–1707. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gu C, Feng L, Peng H, Yang H, Feng Z and
Yang Y: MTDH is an oncogene in multiple myeloma, which is
suppressed by Bortezomib treatment. Oncotarget. 7:4559–4569. 2016.
View Article : Google Scholar :
|
|
25
|
Pichiorri F, Suh SS, Rocci A, De Luca L,
Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder
H, et al: Downregulation of p53-inducible microRNAs 192, 194, and
215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma
development. Cancer Cell. 18:367–381. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
27
|
Jagannathan S, Vad N, Vallabhapurapu S,
Vallabhapurapu S, Anderson KC and Driscoll JJ: MiR-29b replacement
inhibits proteasomes and disrupts aggresome+autophagosome formation
to enhance the antimyeloma benefit of bortezomib. Leukemia.
29:727–738. 2015. View Article : Google Scholar :
|
|
28
|
Misiewicz-Krzeminska I, Sarasquete ME,
Quwaider D, Krzeminski P, Ticona FV, Paíno T, Delgado M, Aires A,
Ocio EM, García-Sanz R, et al: Restoration of microRNA-214
expression reduces growth of myeloma cells through positive
regulation of P53 and inhibition of DNA replication. Haematologica.
98:640–648. 2013. View Article : Google Scholar :
|
|
29
|
Zhang Q, Wang LQ, Wong KY, Li ZY and Chim
CS: Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple
myeloma. J Clin Pathol. 68:557–561. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chi J, Ballabio E, Chen XH, Kušec R,
Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F,
et al: MicroRNA expression in multiple myeloma is associated with
genetic subtype, isotype and survival. Biol Direct. 6:232011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao JJ and Carrasco RD: Crosstalk between
microRNA30a/b/c/ d/e-5p and the canonical Wnt pathway: Implications
for multiple myeloma therapy. Cancer Res. 74:5351–5358. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kubiczkova L, Kryukov F, Slaby O,
Dementyeva E, Jarkovsky J, Nekvindova J, Radova L, Greslikova H,
Kuglik P, Vetesnikova E, et al: Circulating serum microRNAs as
novel diagnostic and prognostic biomarkers for multiple myeloma and
monoclonal gammopathy of undetermined significance. Haematologica.
99:511–518. 2014. View Article : Google Scholar :
|
|
33
|
Qu X, Zhao M, Wu S, Yu W, Xu J, Xu J, Li J
and Chen L: Circulating microRNA 483-5p as a novel biomarker for
diagnosis survival prediction in multiple myeloma. Med Oncol.
31:2192014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yyusnita N, Norsiah, Zakiah I, Chang KM,
Purushotaman VS, Zubaidah Z and Jamal R: MicroRNA (miRNA)
expression profiling of peripheral blood samples in multiple
myeloma patients using microarray. Malays J Pathol. 34:133–143.
2012.
|
|
35
|
Sevcikova S, Kubiczkova L, Sedlarikova L,
Slaby O and Hajek R: Serum miR-29a as a marker of multiple myeloma.
Leuk Lymphoma. 54:189–191. 2013. View Article : Google Scholar
|
|
36
|
Su SF, Chang YW, Andreu-Vieyra C, Fang JY,
Yang Z, Han B, Lee AS and Liang G: miR-30d, miR-181a and
miR-199a-5p cooperatively suppress the endoplasmic reticulum
chaperone and signaling regulator GRP78 in cancer. Oncogene.
32:4694–4701. 2013. View Article : Google Scholar :
|
|
37
|
Xuan H, Xue W, Pan J, Sha J, Dong B and
Huang Y: Downregulation of miR-221, -30d, and -15a contributes to
pathogenesis of prostate cancer by targeting Bmi-1. Biochemistry
(Mosc). 80:276–283. 2015. View Article : Google Scholar
|
|
38
|
Yao J, Liang L, Huang S, Ding J, Tan N,
Zhao Y, Yan M, Ge C, Zhang Z, Chen T, et al: MicroRNA-30d promotes
tumor invasion and metastasis by targeting Galphai2 in
hepatocellular carcinoma. Hepatology. 51:846–856. 2010.PubMed/NCBI
|
|
39
|
Chen D, Guo W, Qiu Z, Wang Q, Li Y, Liang
L, Liu L, Huang S, Zhao Y and He X: MicroRNA-30d-5p inhibits tumour
cell proliferation and motility by directly targeting CCNE2 in
non-small cell lung cancer. Cancer Lett. 362:208–217. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yu C, Liu Y, Tan H, Li G, Su Z, Ren S, Zhu
G, Tian Y, Qiu Y and Zhang X: Metadherin regulates metastasis of
squamous cell carcinoma of the head and neck via AKT signalling
pathway-mediated epithelial-mesenchymal transition. Cancer Lett.
343:258–267. 2014. View Article : Google Scholar
|
|
41
|
Xu H, Liu C, Zhang Y, Guo X, Liu Z, Luo Z,
Chang Y, Liu S, Sun Z and Wang X: Let-7b-5p regulates proliferation
and apoptosis in multiple myeloma by targeting IGF1R. Acta Biochim
Biophys Sin (Shanghai). 46:965–972. 2014. View Article : Google Scholar
|
|
42
|
Hu Y, Lin J, Fang H, Fang J, Li C, Chen W,
Liu S, Ondrejka S, Gong Z, Reu F, et al: Targeting the
MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in
multiple myeloma. Leukemia. Mar 22–2018, Epub ahead of print.
View Article : Google Scholar
|
|
43
|
Li WF, Ou Q, Dai H and Liu CA:
Lentiviral-mediated short hairpin RNA knockdown of MTDH inhibits
cell growth and induces apoptosis by regulating the PTEN/AKT
pathway in hepatocellular carcinoma. Int J Mol Sci. 16:19419–19432.
2015. View Article : Google Scholar :
|
